References
- Kirzinger L, Schotz S, Schalke B. Pure ocular myasthenia gravis. Neurol Int Open. 2018;2:E51–E55. doi:10.1055/s-0043-122245
- Peeler CE, Lott LBD, Eggenberger ER, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015;72(10):1170–1174. doi:10.1001/jamaneurol.2015.1444
- Jaretzki AIII, Barohn RJ, Sanders DB, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16–23. doi:10.1212/WNL.55.1.16
- Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. doi:10.3389/fimmu.2020.00212
- Apinyawasisuk S, Chongpison Y, Thitisaksakul C, et al. Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol. 2020;209:10–17. doi:10.1016/j.ajo.2019.09.019
- Kisabay A, Ozdemir HN, Gokcay F, et al. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic. Acta Neurol Belg. 2022;122(2):337–344. doi:10.1007/s13760-020-01582-1
- Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243–248. doi:10.1001/archneur.60.2.243
- Hendricks TM, Bhatti MT, Chen JJ, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population based study. Am J Ophthalmol. 2019;205:99–105. doi:10.1016/j.ajo.2019.04.017
- Amin S, Aung M, Malik H, et al. Myasthenia gravis and its association with thyroid diseases. Cureus. 2020;12(9):e10248. doi:10.7759/cureus.10248
- Okumura M, Fujii Y, Shiono H, et al. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg. 2008;56(4):143–150. doi:10.1007/s11748-007-0185-8
- Hakian-Tialaki K. The choice of methods in determining the optimal cutoff value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2018;27(8):2374–2383. doi:10.1177/0962280216680383
- Angum F, Khan T, Hussain A, et al. The prevalence of autoimmune disorders in women: a narrative review. Cureus. 2020;12(5):e8094. doi:10.7759/cureus.8094
- Song Y, Zhou L, Chen Z, et al. Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. J Thorac Dis. 2016;8(3):314–322. doi:10.21037/jtd.2016.03.03
- Zhang J, Zhang H, Zhang P, et al. Thymectomy in ocular myasthenia gravis - prognosis and risk factors analysis. Orphanet J Rare Dis. 2022;17(1):309. doi:10.1186/s13023-022-02454-y
- Feng X, Huan X, Zhao C, et al. Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China. Eur Neurol. 2020;83(2):182–188. doi:10.1159/000507853
- Chen YP, Wei DN, Chen B. The clinical features of myasthenia gravis associated with thyroid abnormalities. Zhonghua Nei Ke Za Zhi. 2010;49(7):602–605.